Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019

JAMA. 2019 May 28;321(20):2025-2027. doi: 10.1001/jama.2019.4492.

Abstract

This study describes point-of-sale prices for orally administered anticancer drugs offered through Medicare Part D and out-of-pocket changes in spending as a result of decreasing coinsurance and price changes between 2010 and 2019.

Publication types

  • Letter

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / economics*
  • Formularies as Topic
  • Health Expenditures / statistics & numerical data*
  • Medicare Part D / economics*
  • Prescription Drugs / economics
  • Prescription Fees / statistics & numerical data*
  • United States

Substances

  • Antineoplastic Agents
  • Prescription Drugs